Company intelligence / Profile preview

MetrioPharm AG

Zürich, Zurich, Switzerlandmetriopharm.com ↗

Ownership: Private
Employees: ~20
Development stage: Other

Overview

Completed three Phase II studies with lead compound MP1032 showing efficacy in inflammatory and infectious diseases with excellent safety profile. Recent COVID-19 trial (CT-05) showed comparable efficacy to remdesivir with patients discharged 2.4 days earlier and 4 days shorter ICU stays.

Therapeutic areas: GastroenterologyPulmonologyRheumatologyImmunologyDermatologyRare DiseasesNeurologyInfectious Diseases
Modalities: Small molecules (oral and intravenous)
Industry: Biotech

Drug pipeline

1 asset

mp1032

Beyond the preview

Go deeper on MetrioPharm AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MetrioPharm AG.